Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Biotech
UCB enters TCE space with $1.1B deal for autoimmune candidate
UCB has entered the red-hot T-cell engager space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate.
James Waldron
Mar 4, 2026 8:20am
Boehringer's $500M pact for oral approach to autoimmune disease
Feb 26, 2026 7:00am
Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study
Feb 24, 2026 9:15am
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
Feb 9, 2026 8:41am
Quell halts transplant trial to focus on 'chill not kill' Treg
Feb 5, 2026 6:00am
FDA to ‘carefully shepherd’ CAR-T for autoimmune disease: Prasad
Feb 3, 2026 11:40am
